Τίτλος:
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m2) and dexamethasone (once-weekly Kd70 mg/m2) improved progression-free survival compared with twice-weekly carfilzomib (27 mg/m2) and dexamethasone (twice-weekly Kd27 mg/m2) in patients with relapsed and refractory multiple myeloma (RRMM; median, 11.2 versus 7.6 months; hazard ratio [HR] = 0.69; 95% confidence interval, 0.54–0.88; P = 0.0029). Once-weekly dosing also improved response rates and depth of response. We performed a subgroup analysis from A.R.R.O.W. according to age (<65, 65–74, or ≥75 years), renal function (creatinine clearance <50, ≥50–<80, or ≥80 mL/min), number of prior therapies (2 or 3), and bortezomib-refractory status (yes or no). Compared with twice-weekly Kd27 mg/m2, once-weekly Kd70 mg/m2 reduced the risk of progression or death (HR = 0.60–0.85) and increased overall response rates in nearly all the examined subgroups, consistent with reports in the overall A.R.R.O.W. population. The safety profiles of once-weekly Kd70 mg/m2 across subgroups were also generally consistent with those in the overall population. Findings from this subgroup analysis generally demonstrate a favorable benefit–risk profile of once-weekly Kd70 mg/m2, further supporting once-weekly carfilzomib dosing as an appropriate treatment option for patients with RRMM, regardless of baseline patient and disease characteristics. © 2020, The Author(s).
Συγγραφείς:
Dimopoulos, M.A.
Niesvizky, R.
Weisel, K.
Siegel, D.S.
Hajek, R.
Mateos, M.-V.
Cavo, M.
Huang, M.
Zahlten-Kumeli, A.
Moreau, P.
Περιοδικό:
Blood cancer journal
Εκδότης:
Springer Nature BV
Λέξεις-κλειδιά:
bortezomib; carfilzomib; creatinine; dexamethasone; carfilzomib; oligopeptide, acute kidney failure; adult; aged; anemia; Article; cancer chemotherapy; cancer combination chemotherapy; cancer risk; cancer survival; controlled study; creatinine clearance; drug safety; drug withdrawal; female; heart failure; human; hypertension; ischemic heart disease; major clinical study; male; mortality risk; multiple cycle treatment; multiple myeloma; neutropenia; peripheral neuropathy; phase 3 clinical trial (topic); progression free survival; pulmonary hypertension; randomized controlled trial (topic); risk reduction; thrombocytopenia; treatment response; disease exacerbation; mortality; multiple myeloma; very elderly, Aged; Aged, 80 and over; Disease Progression; Female; Humans; Male; Multiple Myeloma; Oligopeptides; Progression-Free Survival
DOI:
10.1038/s41408-020-0300-y
